- BMO Capital Markets analyst Keith Bachman retained a Market Perform rating on the shares of Genpact Limited G, lowering the price target to $46 from $53.
- After reiteration of FY23 guidance in the first quarter, the analyst cautioned that the 2H implied revenue ramp raises some risk, even with solid March quarter bookings.
- While large deals and long-natured contracts in 2H is a positive, Genpact has to pave through an "incrementally harder" path to meet guidance going ahead.
- Given the above risks, the analyst does not envision an upside for the firm.
- The analyst notes there is an incremental risk to the guide, as well as risk of gen AI more broadly in IT services longer term.
- However, lower attrition and moving margins are expected to buoy optimism for Genpact.
- Most of the margin expansion will come from an improved mix on existing services to offset large deal dilutive pricing, including more onshore delivery, as well as SG&A efficiency, the analyst added.
- Price Action: G is trading lower by 7.6% to $36.02 in the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in